[Management of residual masses of testis germ cell tumors].

Principes de prise en charge des masses résiduelles des tumeurs germinales du testicule.

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 18 07 2018
revised: 27 10 2019
accepted: 30 10 2019
pubmed: 29 12 2019
medline: 7 3 2020
entrez: 29 12 2019
Statut: ppublish

Résumé

A residual mass (RM) is an abnormal image with a transverse axis of more than 1cm trans that remains visible on the CT scan performed after chemotherapy for metastatic germ cell tumors. Their management depends on the histology of the initial tumor. In the case of a non-seminomatous germ cell tumor, all residual lesions must be resected if the tumor markers are negative. The surgery usually begins with a retroperitoneal lymphadenectomy. This lymphadenectomy is a programed regional surgery and not the only resection of visible masses. All RM must be resected, regardless of their location, and may require successive actions. In order to limit its morbidity, modifications on the extent of the lymphadenectomy and the use of minimally invasive approaches are proposed by some center. When the initial tumor is a pure seminoma the attitude is different: the decay of the masses in post chemotherapy is often postponed. If lesions less than 3cm can be monitored, the others benefit from 18FDG PET at the end of chemotherapy: a positive attachment to PET is suspected of the presence of residual active tissue. The surgery of these RM is curative. If its extent is precise in the case of non-seminomatous tumor, it is more controversial in the case of seminoma. In the case of residual markers, surgery has a place in very specific situations.

Identifiants

pubmed: 31882267
pii: S0007-4551(19)30414-X
doi: 10.1016/j.bulcan.2019.10.010
pii:
doi:

Substances chimiques

Biomarkers, Tumor 0
Radiopharmaceuticals 0
Fluorodeoxyglucose F18 0Z5B2CJX4D

Types de publication

Journal Article Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

215-223

Informations de copyright

Copyright © 2019 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Lancelot Tremeau (L)

Hôpital Nord, service d'urologie, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France. Electronic address: lancelot.tremeau@orange.fr.

Nicolas Mottet (N)

Hôpital Nord, service d'urologie, avenue Albert-Raimond, 42270 Saint-Priest-en-Jarez, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH